The DOI matches its Crossref record.
Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease
Open accessAbstract
BACKGROUND: HIV-associated multicentric Castleman disease is a rare lymphoproliferative disorder with marked systemic symptoms attributed to cytokine disarray. Many therapeutic approaches in small series of patients have proved largely unsuccessful to date. OBJECTIVE: To investigate the efficacy and clinicopathologic variables associated with first-line treatment for HIV-associated multicentric Castleman disease with the anti-CD20 monoclonal antibody rituximab. DESIGN: Single-group, open-label, phase II trial. SETTING: 3 teaching hospitals in England. PATIENTS: Previously untreated patients with histologically proven HIV-associated multicentric Castleman disease. INTERVENTION: 4 infusions of rituximab, 375 mg per m2 of body surface area, at weekly intervals. MEASUREMENTS: Response was evaluated clinically and radiologically and by measuring plasma Kaposi sarcoma-associated herpesvirus viral load. RESULTS: 21 consecutive patients (18 men) with plasmablastic multicentric Castleman disease were recruited. The median follow-up was 12 months (range, 1 to 49 months). One patient died before completing therapy, 20 achieved remission of symptoms, and 14 (67%) achieved a radiologic response. The overall and disease-free survival rates at 2 years were 95% (95% CI, 86% to 100%) and 79% (CI, 49% to 100%), respectively. Plasma acute-phase proteins, immunoglobulins, and Kaposi sarcoma-associated herpesvirus viral load decreased after rituximab therapy. The main adverse effect was reactivation of Kaposi sarcoma. LIMITATION: The study had no comparison group. CONCLUSION: Rituximab may be clinically valuable as initial therapy for HIV-associated multicentric Castleman disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Dispenzieri, A., & Fajgenbaum, D. C. (2020) · Blood · doi:10.1182/blood.2019000931 · Cited by 487
van Rhee, F., Voorhees, P., Dispenzieri, A., Fosså, A., Srkalovic, G., Ide, M., Munshi, N., Schey, S., Streetly, M., Pierson, S. K., et al. (2018) · Blood · doi:10.1182/blood-2018-07-862334 · Cited by 426
Uldrick, T. S., Wang, V., O’Mahony, D., Aleman, K., Wyvill, K. M., Marshall, V., Steinberg, S. M., Pittaluga, S., Maric, I., Whitby, D., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/654798 · Cited by 304
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Polizzotto, M. N., Uldrick, T. S., Wang, V., Aleman, K., Wyvill, K. M., Marshall, V., Pittaluga, S., O’Mahony, D., Whitby, D., Tosato, G., et al. (2013) · Blood · doi:10.1182/blood-2013-08-519959 · Cited by 158
“6) 100 (6-567) 3 (15) 198 (91-338) (abnormal if ,161 3 10(3) cells/mL) Leukocytes (10(3) cells/mL)‖ 11 (32.”
Metadata
- Authors
- Bower, M., Powles, T., Williams, S., Davis, T. N., Atkins, M., Montoto, S., Orkin, C., Webb, A., Fisher, M., Nelson, M., Gazzard, B., Stebbing, J., & Kelleher, P.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-12-18
- Volume
- 147
- Issue
- 12
- Pages
- 836-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2126764900
- Cited by
- 197
- References
- 0
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease. https://app.cochat.ai/papers/10.7326/0003-4819-147-12-200712180-00003
- The paper
- Bower, M., Powles, T., Williams, S., Davis, T. N., Atkins, M., Montoto, S., Orkin, C., Webb, A., Fisher, M., Nelson, M., Gazzard, B., Stebbing, J., & Kelleher, P. (2007). Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-12-200712180-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.